- CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy based on the results of a large, randomized Phase 3 trial, METEOR
- Cabometyx™ (cabozantinib) is the first and only multi-kinase inhibitor with established clinical benefits demonstrated for all three key efficacy endpoints: overall survival (OS), progression-free survival (PFS) and objective response rate (ORR)
- Cabometyx™ (cabozantinib) significantly improved overall survival across all evaluated patient subgroups
Catalyst
Slingshot members are tracking this event:
Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cabometyx, Cabozantinib, Rcc, Vegf-targeted Therapy, Chmp
